Givoly: Medivisor's last four biopharma deals closed inbound within three months
Tal Givoly · 1479 Are they actually better than WebMD w $500k+ in Revenue? · Aug 12, 2019 · at 13:34
Tal Givoly, co-founder and CEO of Medivisor, discusses the startup's sales cycle and customer acquisition channels with Nathan Latka.
0:00 / 0:23exact quote · 23.2s
720p mp4 · rendered on demand · StarZero watermark
“So far, the interesting thing is that the last four deals have come to us and closed within three months. So without us even meeting them. So yeah, we had phone conversations and so on, but the last deals have actually discovered us online found out that we could help them and engaged with us.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Tal Givoly
Givoly: WebMD's information is static and fails to reflect new research
“WebMD's information is essentially fairly static. There's a page about lymphoma and about treatment options, but it doesn't get updated every research paper that gets updated.”
Givoly: Biopharma will eventually become Medivisor's largest revenue stream
“So, ultimately, over time, it's going to be, ah, basically, ah, the biopharma is gonna be larger.”
Givoly: Medivisor revenue is split fifty-fifty between licensing and biopharma
“Today it's about fifty-fifty.”
Givoly: Medivisor has over 130,000 subscribers across 129 countries
“We're, by the way, helping over 130,000 subscribers. In a 129 countries, though the vast majority are in the US.”
Givoly: Medivisor's clinical trial acceleration deals are six-figure contracts
“It's usually bigger, longer deals to longer term engagement. So, for example, a clinical trial that wants to be accelerated, it could be a six-figure deal to work with us to help accelerate that trial.”
Givoly: Leukemia & Lymphoma Society licenses Medivisor's content
“The Leukemia Lymphoma Society, they have an online community that they're trying to cultivate. They sponsor blood cancer as a med advisor, and they license the content that we provide so that we could feed it into their community members.”